Nucala Injection, Solution
Product Images NDC 0173-0892

Product Visual Gallery

This gallery contains 34 technical images submitted to the FDA as part of the official labeling for Nucala (NDC 0173-0892). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Kaplan-meier Cumulative Incidence Curve For Time To First Exacerbation (trial 2) (Nucala Spl Graphic 01)

A line graph depicting the probability of event (%) over time to event (weeks) comparing Placebo, Mepolizumab 75 mg IV, and NUCALA 100 mg SC. The graph includes error bars indicating 95% confidence intervals and the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 2. Kaplan-meier Plot Of Time To First Relapse (Nucala Spl Graphic 02)

A Kaplan-Meier probability plot showing the 'Probability of Event (%)' over 'Time to Event (Weeks)' for two groups: Placebo and NUCALA 100 mg SC. The plot includes error bars indicating 95% confidence intervals and displays the number of patients at risk over time for both groups.*

FDA Label Image

Nucala 100 mg Per Vial Carton (Nucala Spl Graphic 03)

A Kaplan-Meier survival curve comparing the probability of event occurrence over time (in weeks) between placebo and Nucala 300 mg subcutaneous injection groups. The graph includes error bars representing 95% confidence intervals and a table of patients at risk at various time points.*

FDA Label Image

Nucala Spl Graphic 04

A line graph showing the probability of an event (%) over time in weeks for Nucala 300 mg SC injection compared to placebo. The chart includes error bars indicating 95% confidence intervals and lists the number of patients at risk for each group at various time points up to 32 weeks.*

FDA Label Image

Nucala Spl Graphic 05

An instructional diagram showing a Nucala injection syringe before and after use. It labels the syringe parts including the label, stopper, inspection window displaying medicine inside, yellow needle guard, and clear needle cap. After use, the yellow indicator becomes visible indicating the injection is complete.*

FDA Label Image

Nucala Spl Graphic 06

Instructional diagram showing steps to remove a Nucala auto-injector from its packaging. The left panel illustrates a box with security seals and advises to ensure seals are intact. The right panel shows peeling off the plastic cover and taking the auto-injector out of the tray, with hand illustrations guiding the process.*

FDA Label Image

Nucala Spl Graphic 07

An instructional illustration showing a Nucala injection pen with a focus on checking the expiration date labeled as Month-Year. It also advises waiting 30 minutes with the injection pen before use. The image emphasizes verifying the expiration date and medicine before administration.*

FDA Label Image

Nucala Spl Graphic 08

An anatomical diagram showing recommended subcutaneous injection sites for Nucala (mepolizumab) on the human body. Highlighted areas include the upper arms, the abdomen around the navel excluding a central area, and the front of the thighs.*

FDA Label Image

Nucala Spl Graphic 09

An instructional diagram showing handwashing with soap under running water on the left side, followed by a hand using an antiseptic wipe on an arm injection site on the right side. The images illustrate steps to clean hands and prepare the skin before a subcutaneous injection.*

FDA Label Image

Nucala Spl Graphic 10

An instructional illustration showing two hands preparing a subcutaneous injection with a prefilled syringe. One hand holds the syringe upright, and the other is removing the cap from the needle, indicated by an orange arrow pointing downward.*

FDA Label Image

Nucala Spl Graphic 11

An instructional illustration showing hands using a Nucala injection device subcutaneously. The left side depicts pressing the device down until fully depressed, and the right side shows continuing to press until the first "Click" is heard, indicating proper injection initiation.*

FDA Label Image

Nucala Spl Graphic 12

Instructional illustration showing how to use the Nucala injection, solution. It depicts hands holding the device, pressing it down until the second "click" occurs, then continuing to hold down and count to five before lifting off, indicating the correct injection technique for the subcutaneous dosage form.*

FDA Label Image

Nucala Spl Graphic 13

Illustration showing a sharps disposal container labeled "SHARPS DISPOSAL CONTAINER" with a pen injector and its cap positioned above it, indicating proper disposal of injection needles or devices.*

FDA Label Image

Nucala Spl Graphic 14

An instructional diagram showing a Nucala injection, solution subcutaneous syringe labeled with parts including white plunger, white finger grip, stopper, inspection window, automatic needle guard, and gray needle cap. The diagram also illustrates the syringe before use and after use, highlighting the activation and retraction of the automatic needle guard.*

FDA Label Image

Nucala Spl Graphic 15

Illustration showing steps to open the Nucala injection packaging. The first panel advises ensuring that security seals on the box are intact. The second panel demonstrates peeling off the plastic cover and removing the syringe from the tray for use.*

FDA Label Image

Nucala Spl Graphic 16

Instructional diagram showing the use of a prefilled syringe for Nucala (mepolizumab) injection. The first illustration highlights checking the expiration date on the syringe, and the second indicates to wait 30 minutes after administration. The syringe depicted is consistent with a subcutaneous injection device.*

FDA Label Image

Nucala Spl Graphic 17

Illustration showing recommended subcutaneous injection sites on the human body. Highlighted areas include the upper arms, abdomen (excluding a 2-inch area around the navel), and the front of the thighs. This visual guide helps identify appropriate locations for administering subcutaneous injections such as Nucala (mepolizumab) injection solution.*

FDA Label Image

Nucala Spl Graphic 18

An instructional illustration showing hand washing with soap and water on the left and wiping an area of skin with an alcohol swab on the right. The image likely depicts steps for preparing an injection site.*

FDA Label Image

Nucala Spl Graphic 19

An instructional illustration showing hands preparing a syringe for use. One hand holds a capped syringe, and the other hand is removing the cap by pulling it upward, indicated by an orange arrow pointing up.*

FDA Label Image

Nucala Spl Graphic 20

An instructional illustration showing how to administer a subcutaneous injection using a syringe. The first panel depicts inserting the needle at a 45-degree angle into the skin. The second panel shows pushing the plunger to inject the solution. The syringe is held with fingers positioned for injection control.*

FDA Label Image

Nucala Spl Graphic 21

Illustration showing injection instructions for Nucala (mepolizumab) solution, emphasizing that the white plunger must be fully depressed and then pulled straight up to complete the injection process.*

FDA Label Image

Nucala Spl Graphic 22

Illustration showing a red sharps disposal container labeled "SHARPS DISPOSAL CONTAINER" with a syringe being disposed into it, emphasizing safe disposal of injection equipment for subcutaneous administration.*

FDA Label Image

Nucala Spl Graphic 23

An instructional illustration showing a syringe before and after use. The 'Before use' image labels parts including the white plunger, white finger grip, stopper, inspection window containing medicine, automatic needle guard, and gray needle cap with needle inside. The 'After use' image shows the syringe with the automatic needle guard activated and retracted, covering the needle.*

FDA Label Image

Nucala Spl Graphic 24

An instructional diagram showing how to remove a syringe from its packaging tray for Nucala injection, solution. It highlights checking that security seals on the box are intact before peeling off the plastic cover and taking the syringe out of the tray.*

FDA Label Image

Nucala Spl Graphic 25

An instructional diagram for a Nucala (mepolizumab) subcutaneous injection showing a syringe. The left panel advises checking the expiration date and medicine on the syringe, while the right panel instructs to wait 30 minutes, represented by a clock icon and text.*

FDA Label Image

Nucala Spl Graphic 26

An instructional illustration showing possible subcutaneous injection sites on a human body for Nucala (mepolizumab) injection. Highlighted areas include both upper arms, the abdomen, and the front of both thighs.*

FDA Label Image

Nucala Spl Graphic 27

An instructional illustration showing hand hygiene and skin preparation steps before injection. The left panel depicts hands under running water with soap, and the right panel shows applying an alcohol wipe to the skin area to disinfect before injection.*

FDA Label Image

Nucala Spl Graphic 28

An instructional illustration depicting a hand holding a syringe with the other hand removing or attaching a cap from the syringe needle. An orange arrow indicates the motion of pulling the cap upwards.*

FDA Label Image

Nucala Spl Graphic 29

An instructional illustration showing how to properly use the Nucala injection syringe. The left side demonstrates positioning the syringe at a 45-degree angle before injection. The right side shows pressing down the plunger to administer the injection subcutaneously.*

FDA Label Image

Nucala Spl Graphic 30

An instructional illustration showing the proper use of a prefilled syringe for Nucala (mepolizumab) injection. The left side emphasizes ensuring the white plunger is fully depressed, while the right side indicates pulling back or removing a cover from the syringe tip with an upward arrow.*

FDA Label Image

Nucala Spl Graphic 31

Illustration showing a red sharps disposal container with a white label reading 'Sharps Disposal Container.' Above the container, a syringe with a needle cap is depicted, indicating proper disposal of injection needles.*

FDA Label Image

Nucala Spl Graphic 32

Nucala (mepolizumab) for Injection 100 mg per vial is a single-dose vial for subcutaneous injection after reconstitution. The label highlights the 100 mg/mL reconstituted solution and lists inactive ingredients including polysorbate 80, sodium phosphate dibasic heptahydrate, and sucrose. It is labeled for prescription use by GlaxoSmithKline LLC and contains one vial per package.*

FDA Label Image

Nucala Spl Graphic 33

Nucala 100 mg/mL (mepolizumab) prefilled autoinjector injection solution. The packaging label indicates it is for subcutaneous use only and includes 1 single-dose 1 mL prefilled autoinjector, along with instructions for use, prescribing information, and patient information. The labeler is GlaxoSmithKline LLC.*

FDA Label Image

Nucala Spl Graphic 34

Nucala 40 mg/0.4 mL injection in a prefilled syringe, containing the active ingredient mepolizumab for subcutaneous use. The label from GlaxoSmithKline LLC includes directions to 'press here to open' and lists package contents, including one single-dose 0.4 mL prefilled syringe, instructions for use, prescribing information, and patient information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.